Close

Amgen declares positive results for 2 Phase 3 BLINCYTO® (blinatumomab) studies

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

News that has taken the Pharmaceutical sector by storm, Amgen has announced positive results for 2 phase 3 BLINCYTO® (blinatumomab) studies in pediatric patients with relapsed acute lymphoblastic leukemia.

Amgen announced the results of a pre-specified interim analysis of an open-label, randomized, controlled global multicenter phase 3 trial showed that the primary endpoint of event-free survival was met. The study analyzed and evaluated the adequacy of BLINCYTO® (blinatumomab) the conventional consolidation chemotherapy in pediatric patients with high risk. Enrollment was aborted early due to encouraging efficacy in the BLINCYTO arm and as a result of a recommendation from the Independent Data Monitoring Committee. Follow up to all this will continue as per the as compared to protocol.

Apart from this, a random Phase 3 trial which was conducted by the Children’s Oncology Group using BLINCYTO in pediatric B-cell, all patients at first relapse closed to accrual for the high and intermediate risk-arm based on the recommendation by COG DMC. The decision was based on a strong trend towards improved disease-free survival and also improved overall survival, lower toxicity and comparatively better minimal residual disease clearance for BLINCYTO compared to chemotherapy.

As per David M Reese, M.D, executive vice president of R & D at Amgen the results of the studies conducted are remarkable. Children who relapse with acute lymphoblastic leukemia face poor prognosis and there is always a requirement of additional treatment options at least for those that are identified as high-risk. What has been found out has the potential to be practice-changing and may provide a treatment approach superior to chemotherapy that might prevent further relapse.

 

Latest stories

Related stories

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back